Aprea Therapeutics Inc (APRE NASDAQ) stock market data APIs
$0.4829
-0(-0%)
as of October 30, 2026
Try our APIs with
free plan!
Aprea Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Prev. Close
0.4829
Open
0.4791
High
0.521
Low
0.4572
52 wk Range
0.41-1.45
Market Cap
6 102 K
Shares Outstanding
12 591 K
Revenue
5 185
EPS
-0.07
Beta
1.629
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Aprea Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Aprea Therapeutics Inc data using free add-ons & libraries
Get Aprea Therapeutics Inc Fundamental Data
Aprea Therapeutics Inc Fundamental data includes:
- Net Revenue: 5 185
- EBITDA: -13 201 041
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: -0.22
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aprea Therapeutics Inc News
New
Aprea Advances APR-1051; Phase 1 Enrollment Accelerates
(RTTNews) - Aprea Therapeutics, Inc. (APRE), a clinical-stage precision medicine oncology company developing targeted therapies for biomarker-defined cancers, reported second-quarter 2026 financial re...
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $0.75 per share a year ago. The...
Lipocine Appoints Michael J. Grissinger to Board of Directors
SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral del...
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Respons...
Get Aprea Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.